{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:13:11Z","timestamp":1787955191991,"version":"build-2784847793"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373286"],"award-info":[{"award-number":["82373286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70132-9","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:03:44Z","timestamp":1772273024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Yaning","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanqian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5619-5834","authenticated-orcid":false,"given":"Zilong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-9180","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5284-4533","authenticated-orcid":false,"given":"Chaolong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0179-5266","authenticated-orcid":false,"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-1307","authenticated-orcid":false,"given":"Chenghao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"70132_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","volume":"28","author":"SJ Bagley","year":"2022","unstructured":"Bagley, S. J. et al. Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin. Cancer Res 28, 594\u2013602 (2022).","journal-title":"Clin. Cancer Res"},{"key":"70132_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fonc.2015.00055","volume":"5","author":"NR Parker","year":"2015","unstructured":"Parker, N. R., Khong, P., Parkinson, J. F., Howell, V. M. & Wheeler, H. R. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 5, 55 (2015).","journal-title":"Front Oncol."},{"key":"70132_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26\u201341 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"70132_CR4","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017).","journal-title":"JAMA"},{"key":"70132_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","volume":"33","author":"SJ Russell","year":"2018","unstructured":"Russell, S. J. & Barber, G. N. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 33, 599\u2013605 (2018).","journal-title":"Cancer Cell"},{"key":"70132_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med 379, 150\u2013161 (2018).","journal-title":"N. Engl. J. Med"},{"key":"70132_CR7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo, T. et al. Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med 28, 1630\u20131639 (2022).","journal-title":"Nat. Med"},{"key":"70132_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","volume":"18","author":"TS van Solinge","year":"2022","unstructured":"van Solinge, T. S., Nieland, L., Chiocca, E. A. & Broekman, M. L. D. Advances in local therapy for glioblastoma - taking the fight to the tumour. Nat. Rev. Neurol. 18, 221\u2013236 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"70132_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 Immunotherapy. Cell 170, 1109\u20131119.e1110 (2017).","journal-title":"Cell"},{"key":"70132_CR10","doi-asserted-by":"crossref","unstructured":"Ju, F. et al. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. J. Immunother. Cancer 10, e004762 (2022).","DOI":"10.1136\/jitc-2022-004762"},{"key":"70132_CR11","doi-asserted-by":"publisher","first-page":"226ra232","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med 6, 226ra232 (2014).","journal-title":"Sci. Transl. Med"},{"key":"70132_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"18","author":"K Twumasi-Boateng","year":"2018","unstructured":"Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C. & Nelson, B. H. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer 18, 419\u2013432 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"70132_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06954-z","volume":"9","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat. Commun. 9, 4682 (2018).","journal-title":"Nat. Commun."},{"key":"70132_CR14","doi-asserted-by":"crossref","unstructured":"Bommareddy P. K., Aspromonte S., Zloza A., Rabkin S. D., Kaufman H. L. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci. Transl. Med. 10, eaau0417 (2018).","DOI":"10.1126\/scitranslmed.aau0417"},{"key":"70132_CR15","doi-asserted-by":"crossref","unstructured":"Zhang, H. et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl. Med. 9, eaam7996 (2017).","DOI":"10.1126\/scitranslmed.aam7996"},{"key":"70132_CR16","doi-asserted-by":"crossref","unstructured":"Selman, M. et al. Dimethyl fumarate potentiates oncolytic virotherapy through NF-kappaB inhibition. Sci Transl Med 10, eaao1613 (2018).","DOI":"10.1126\/scitranslmed.aao1613"},{"key":"70132_CR17","doi-asserted-by":"crossref","unstructured":"Beug, S. T. et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat. Biotechnol. 32, 182\u2013190 (2014).","DOI":"10.1038\/nbt.2806"},{"key":"70132_CR18","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1073\/pnas.0605496103","volume":"103","author":"G Fulci","year":"2006","unstructured":"Fulci, G. et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12873\u201312878 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70132_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2015.06.009","volume":"28","author":"R Arulanandam","year":"2015","unstructured":"Arulanandam, R. et al. VEGF-mediated induction of PRD1-BF1\/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell 28, 210\u2013224 (2015).","journal-title":"Cancer Cell"},{"key":"70132_CR20","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1111\/febs.13305","volume":"282","author":"R Wallings","year":"2015","unstructured":"Wallings, R., Manzoni, C. & Bandopadhyay, R. Cellular processes associated with LRRK2 function and dysfunction. FEBS J. 282, 2806\u20132826 (2015).","journal-title":"FEBS J."},{"key":"70132_CR21","doi-asserted-by":"crossref","unstructured":"Di Maio R. et al. LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci. Transl. Med. 10, eaar5429 (2018).","DOI":"10.1126\/scitranslmed.aar5429"},{"key":"70132_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa, E., Vila, M., Klein, C. & Rascol, O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 16, 97\u2013107 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"70132_CR23","doi-asserted-by":"crossref","unstructured":"Kingwell K. LRRK2-targeted Parkinson disease drug advances into phase III. Nat Rev Drug Discov, 22, 3\u20135 (2022).","DOI":"10.1038\/d41573-022-00212-0"},{"key":"70132_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings, D. et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci. Transl. Med 14, eabj2658 (2022).","journal-title":"Sci. Transl. Med"},{"key":"70132_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.omto.2019.09.004","volume":"15","author":"Y Luo","year":"2019","unstructured":"Luo, Y. et al. Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma. Mol. Ther. Oncolytics 15, 153\u2013165 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"70132_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","volume":"6","author":"BC Prager","year":"2020","unstructured":"Prager, B. C., Bhargava, S., Mahadev, V., Hubert, C. G. & Rich, J. N. Glioblastoma stem cells: driving resilience through chaos. Trends Cancer 6, 223\u2013235 (2020).","journal-title":"Trends Cancer"},{"key":"70132_CR27","doi-asserted-by":"crossref","unstructured":"Baptista, M. A. S. et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med 12, eaav0820 (2020).","DOI":"10.1126\/scitranslmed.aav0820"},{"key":"70132_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2236-3","volume":"11","author":"J Ma","year":"2020","unstructured":"Ma, J. et al. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 11, 48 (2020).","journal-title":"Cell Death Dis."},{"key":"70132_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111769","volume":"41","author":"D Kwart","year":"2022","unstructured":"Kwart, D. et al. Cancer cell-derived type I interferons instruct tumor monocyte polarization. Cell Rep. 41, 111769 (2022).","journal-title":"Cell Rep."},{"key":"70132_CR30","doi-asserted-by":"publisher","first-page":"e39132","DOI":"10.1371\/journal.pone.0039132","volume":"7","author":"N Dzamko","year":"2012","unstructured":"Dzamko, N. et al. The IkappaB kinase family phosphorylates the Parkinson\u2019s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 7, e39132 (2012).","journal-title":"PLoS One"},{"key":"70132_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101420","volume":"23","author":"A Zeng","year":"2020","unstructured":"Zeng, A. et al. Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience 23, 101420 (2020).","journal-title":"iScience"},{"key":"70132_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41417-021-00351-3","volume":"29","author":"D Mealiea","year":"2022","unstructured":"Mealiea, D. & McCart, J. A. Cutting both ways: the innate immune response to oncolytic virotherapy. Cancer Gene Ther. 29, 629\u2013646 (2022).","journal-title":"Cancer Gene Ther."},{"key":"70132_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.971674","volume":"13","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. The gamble between oncolytic virus therapy and IFN. Front Immunol. 13, 971674 (2022).","journal-title":"Front Immunol."},{"key":"70132_CR34","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/mt.2008.155","volume":"16","author":"A Otsuki","year":"2008","unstructured":"Otsuki, A. et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16, 1546\u20131555 (2008).","journal-title":"Mol. Ther."},{"key":"70132_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1158\/1541-7786.MCR-15-0427","volume":"14","author":"JD Jackson","year":"2016","unstructured":"Jackson, J. D., Markert, J. M., Li, L., Carroll, S. L. & Cassady, K. A. STAT1 and NF-kappaB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol. Cancer Res 14, 482\u2013492 (2016).","journal-title":"Mol. Cancer Res"},{"key":"70132_CR36","doi-asserted-by":"crossref","unstructured":"Shutinoski, B. et al. Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci. Transl. Med. 11, (2019).","DOI":"10.1126\/scitranslmed.aas9292"},{"key":"70132_CR37","doi-asserted-by":"crossref","unstructured":"Weindel, C. G. et al. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis. Elife 9, e51071 (2020).","DOI":"10.7554\/eLife.51071"},{"key":"70132_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jhep.2006.01.037","volume":"45","author":"D Di Bona","year":"2006","unstructured":"Di Bona, D. et al. Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J. Hepatol. 45, 271\u2013279 (2006).","journal-title":"J. Hepatol."},{"key":"70132_CR39","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips, R. L. et al. The JAK-STAT pathway at 30:Much learned, much more to do. Cell 185, 3857\u20133876 (2022).","journal-title":"Cell"},{"key":"70132_CR40","doi-asserted-by":"crossref","unstructured":"Liu, H. N. et al. The tyrosine kinase c-Abl potentiates interferon-mediated antiviral immunity by STAT1 phosphorylation. Iscience 24, 102078 (2021).","DOI":"10.1016\/j.isci.2021.102078"},{"key":"70132_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41531-018-0049-1","volume":"4","author":"JH Kluss","year":"2018","unstructured":"Kluss, J. H. et al. Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. NPJ Parkinsons Dis. 4, 13 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"70132_CR42","doi-asserted-by":"crossref","unstructured":"Dhekne, H. S. et al. Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson\u2019s disease-linked LRRK2 kinase. Elife 12, e87098 (2023).","DOI":"10.7554\/eLife.87098"},{"key":"70132_CR43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498\u2013513 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"70132_CR44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","volume":"588","author":"CK Deniston","year":"2020","unstructured":"Deniston, C. K. et al. Structure of LRRK2 in Parkinson\u2019s disease and model for microtubule interaction. Nature 588, 344\u2013349 (2020).","journal-title":"Nature"},{"key":"70132_CR45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ygeno.2021.11.037","volume":"114","author":"J Yan","year":"2022","unstructured":"Yan, J., Zhao, W., Yu, W., Cheng, H. & Zhu, B. LRRK2 correlates with macrophage infiltration in pan-cancer. Genomics 114, 316\u2013327 (2022).","journal-title":"Genomics"},{"key":"70132_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1180-y","volume":"9","author":"YH Bae","year":"2018","unstructured":"Bae, Y. H. et al. Brain injury induces HIF-1alpha-dependent transcriptional activation of LRRK2 that exacerbates brain damage. Cell Death Dis. 9, 1125 (2018).","journal-title":"Cell Death Dis."},{"key":"70132_CR47","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1007\/s00018-007-7082-2","volume":"64","author":"MA Maynard","year":"2007","unstructured":"Maynard, M. A. & Ohh, M. The role of hypoxia-inducible factors in cancer. Cell Mol. Life Sci. 64, 2170\u20132180 (2007).","journal-title":"Cell Mol. Life Sci."},{"key":"70132_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2018.00249","volume":"8","author":"A Lo Dico","year":"2018","unstructured":"Lo Dico, A., Martelli, C., Diceglie, C., Lucignani, G. & Ottobrini, L. Hypoxia-Inducible Factor-1alpha Activity as a Switch for Glioblastoma Responsiveness to Temozolomide. Front Oncol. 8, 249 (2018).","journal-title":"Front Oncol."},{"key":"70132_CR49","doi-asserted-by":"publisher","first-page":"354re353","DOI":"10.1126\/scitranslmed.aaf6853","volume":"8","author":"M Allen","year":"2016","unstructured":"Allen, M., Bjerke, M., Edlund, H., Nelander, S. & Westermark, B. Origin of the U87MG glioma cell line: Good news and bad news. Sci. Transl. Med 8, 354re353 (2016).","journal-title":"Sci. Transl. Med"},{"key":"70132_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1726168","volume":"9","author":"Y Luo","year":"2020","unstructured":"Luo, Y. et al. Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. Oncoimmunology 9, 1726168 (2020).","journal-title":"Oncoimmunology"},{"key":"70132_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep34531","volume":"6","author":"C Lin","year":"2016","unstructured":"Lin, C. et al. Increasing the Efficiency of CRISPR\/Cas9-mediated precise genome editing of HSV-1 virus in human cells. Sci. Rep. 6, 34531 (2016).","journal-title":"Sci. Rep."},{"key":"70132_CR52","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","volume":"8","author":"C Lin","year":"2020","unstructured":"Lin, C. et al. Intratumoral delivery of a PD-1-blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade. Cancer Immunol. Res 8, 632\u2013647 (2020).","journal-title":"Cancer Immunol. Res"},{"key":"70132_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26003-6","volume":"12","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nat. Commun. 12, 5908 (2021).","journal-title":"Nat. Commun."},{"key":"70132_CR54","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.omto.2021.12.013","volume":"24","author":"AA Stepanenko","year":"2022","unstructured":"Stepanenko, A. A. et al. Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5\/35 and Ad5\/3 over Ad5-delta-24-RGD in primary glioma cultures. Mol. Ther. Oncolytics 24, 230\u2013248 (2022).","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70132-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T23:03:14Z","timestamp":1775775794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70132-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70132"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70132-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H., M.Y., Y.Q., Y.L., J.Z., and N.X. are inventors on patent application submitted by Xiamen University that covers the concept of combining LRRK2 inhibitors and OVs for cancer therapy (Application No. 202310157529.3). The other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3324"}}